The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine, cisplatin (GC) for patients with advanced biliary tract cancer.
 
Toru Otsuru
No Relationships to Disclose
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Akie Kimura
No Relationships to Disclose
 
Chiaki Inagaki
No Relationships to Disclose
 
Naohiro Nishida
No Relationships to Disclose
 
Yoshifumi Iwagami
No Relationships to Disclose
 
Takehiro Noda
No Relationships to Disclose
 
Tadafumi Asaoka
No Relationships to Disclose
 
Kunihito Gotoh
No Relationships to Disclose
 
Shogo Kobayashi
No Relationships to Disclose
 
Hidetoshi Eguchi
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Ono Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)